FHL2抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: P08335(FHL2 Antibody) at dilution 1/2400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P08335(FHL2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08335(FHL2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The FHL2 (Four and a Half LIM Domains 2) antibody is a crucial tool for studying the FHL2 protein, a member of the LIM-only protein family involved in diverse cellular processes. FHL2. characterized by four LIM domains and a half LIM motif, acts as a scaffold or adaptor protein, mediating protein-protein interactions in signaling pathways. It regulates gene expression, cell proliferation, apoptosis, and differentiation by interacting with transcription factors (e.g., β-catenin, androgen receptor), kinases, and structural proteins. FHL2 exhibits tissue-specific expression, with high levels in the heart, ovary, and prostate, and plays roles in cancer progression, cardiovascular disease, and musculoskeletal disorders.

FHL2 antibodies are widely used in research to detect endogenous FHL2 protein in applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate FHL2’s dual role as both a tumor suppressor and promoter, depending on cellular context. For instance, FHL2 suppresses Wnt/β-catenin signaling in some cancers but enhances androgen receptor activity in prostate cancer. Its involvement in fibrosis, hypertrophy, and mechanotransduction pathways further underscores its biomedical relevance. Commercial FHL2 antibodies are typically validated for specificity across human, mouse, and rat samples, enabling cross-species studies. Ongoing research focuses on FHL2’s potential as a therapeutic target or biomarker, particularly in cancers and cardiovascular diseases.